Locations

Showing 18 Locations
Sort by:

  • Branford, Connecticut, USA

    Lighthouse Wellness Spa

  • Canaan, Connecticut, USA

    Josh Flaherty • Nate Bennick • Tim Walsh

  • Centerbrook, Connecticut, USA

    Elizabeth Comstock

  • Connecticut, USA

    Becky Muldoon • Melaina Marion • Heather Carey • Lorri Wilson • Linda • Helen Granskog • Wendy A. Pernerewski, M.S. • Deana Rae • Elizabeth Mauro • Stephanie Clark - Holistic Health and Welness • Meghan Mitchell • Patricia Millix • Lynn Turcotte-Schuh, HC • Rachel Silansky, CHHC • Michelle Matthews, CHHC, LMT, RYT • Michelle Peters • Gina Ledwith • Kaitlin Crean • Cheryl Albino • Linda Yalen • Kalpita • Donna Smith • Janelle Kleiner

  • Farmington, Connecticut, USA

    Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD • Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain • A Safety and Efficacy Study of Xyrem (Sodium Oxybate) to Treat Fibromyalgia.

  • Glastonbury, Connecticut, USA

    Center for Holistic Healthcare

  • Greenwich, Connecticut, USA

    Soleus Capital

    Guy Levy

  • Hamden, Connecticut, USA

    Connecticut Psychiatric

  • Hartford, Connecticut, USA

    Hartford Hospital • Connecticut Children's Medical Center

    Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain • A Study of Ketamine in Patients With Treatment-resistant Depression

  • Milford, Connecticut, USA

    Ketamine Center of Connecticut

    Jeanette Dias

  • New Canaan, Connecticut, USA

    Innovating Capital

    George Lovas

  • New Haven, Connecticut, USA

    Yale University • Alexion Pharmaceuticals

    A Study of Psilocybin for Major Depressive Disorder (MDD) • Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. • The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. • Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy • Ketamine Infusion for Obsessive-Compulsive Disorder • Ketamine Infusion for Social Anxiety Disorder • The Sustained Effects of Ketamine • Ketamine in Borderline Personality Disorder • PET Imaging of mGLuR5 With Drug Challenge • Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine • Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy • Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response • Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects • A Study of Ketamine in Patients With Treatment-resistant Depression • ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) • Ketamine Infusion for Adolescent Depression and Anxiety • Ketamine for Low Mood States in the ER • The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects • Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling • A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers • Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) • Biomarker Assessment of Glutamatergic Target Engagement • Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects • Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression • The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers • Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia • Characterizing Clinical and Pharmacological Neuroimaging Biomarkers • Imaging SV2A in Mood Disorders • Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine • Effects of Repeated Psilocybin Dosing in OCD

  • North Haven, Connecticut, USA

    Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

  • South Windsor, Connecticut, USA

    Lori Calabrese MD, LLC

  • Storrs, Connecticut, USA

    University of Connecticut

  • Trumbull, Connecticut, USA

    Rett Syndrome Research Trust

  • West Haven, Connecticut, USA

    VA Connecticut Healthcare System

    Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder • Psilocybin for the Treatment of Migraine Headache • Repeat Dosing of Psilocybin in Migraine Headache • Effects of Psilocybin in Concussion Headache • Psilocybin for the Treatment of Cluster Headache • Open Label Ketamine Treatment for Major Depressive Disorder in Veterans • Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects • Ketamine for Depression and Alcohol Dependence • Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects • CAP-Ketamine for Antidepressant Resistant PTSD • Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder • The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects • THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis • A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers • Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism • Ketamine/Placebo Family History Positive Study • Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects • N-acetylcysteine and NMDA Antagonist Interactions • GABA-glutamate Interactions and Psychosis • Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

  • Woodbridge, Connecticut, USA

    Connecticut Psychiatric

What Data is Included?